NEW YORK (GenomeWeb) – Leerink today upgraded shares of Bruker to an Outperform rating, noting that the company's operational improvements have begun to show results and that its competitive position in the NMR market has improved significantly with Agilent's exit from this space last year.

Analyst Dan Leonard upgraded the company's stock from a previous Market Perform rating and increased the bank's price target on Bruker's shares to $24 from $21.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

360Dx reports that the US Centers for Medicare & Medicaid Services would cover next-generation sequencing-based cancer panel tests.

The Washington Post reports that a meteorologist is being considered as presidential science and technology advisor.

In PNAS this week: precision medicine strategy to screen for disease risk, genome evolution in Haemophilus influenzae, and more.

Researchers have developed a PCR-based assay to gauge whether manatees are present in waters.